Drug maker Biocon has received a Form 483 from the FDA after an inspection of its manufacturing facility in Malaysia.
Drug maker Biocon has received a Form 483 from the FDA after an inspection of its manufacturing facility in Malaysia. The FDA issues Form 483 when an investigator conducting an inspection has observed conditions that may constitute violations of the Food Drug and Cosmetic Act or related acts.
A brief statement on Biocon’s website said, "The US FDA has completed a pre-approval inspection of our manufacturing facility in Malaysia and issued a Form 483 with 6 observations. As per the normal expectations of the agency, we intend to respond with a corrective and preventive action plan in a timely manner." The drug maker did not elaborate on the nature of the FDA’s observations.
According to Biocon’s website, the Malaysia facility that was the subject of the form will manufacture the company’s insulin products. Biocon first received its certificate of good manufacturing practice compliance for the site from the competent authority of Ireland in April 2017.
However, Cyndrella Carvalho, an analyst with Dolat Capital, told Bloomberg that any deficiencies at the plant could delay FDA approval of the facility, but that the observations made by the agency are unlikely to be serious in nature, as the plant does not yet manufacture any products.
The news of the setback for Biocon comes less than a month after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for Biocon’s insulin glargine follow-on (which is classified as a biosimilar in the European Union), referencing Lantus.
This is not the first Form 483 for Biocon; in 2017, the company received a form for issues related to its Bangalore plant, where the company manufactures its biosimilar monoclonal antibodies, pursuant to an inspection carried out between March 27 and April 7. That document noted 8 observations, including issues with the company’s quality assurance unit.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.